Fig. 1. Up-regulation of METTL3 in chemoresistant AML cells.

A Flow chart for the identification and verification strategy of differentially expressed targets between chemotherapy-resistant AML cells and -sensitive AML cells. Graphical elements were adapted from the RNA-seq (GSE165430, n = 268, Log₂ FC ≥ 2) and RPPA screen (LogFC > 0.25) workflow. Significant: P < 0.05; nonsignificant: P ≥ 0.05. See also Supplemental Fig. S1. B qRT-PCR analysis of METTL3 mRNA expression in CD34 + leukemia cells sorted from pretreatment patients and relapsed patients with de novo AML. Pretreatment patients who achieved CR after induction treatment with standard “7 + 3” chemotherapy were defined as the CR group (n = 17), and NR patients and relapsed patients were defined as the refractory/relapsed group (n = 20). Data are mean ± SD values. P < 0.05 was considered significant, t test. C Western blot analysis and Flow cytometry analysis for the expression of METTL3, n = 3.